Automate Your Wheel Strategy on PHGE
With Tiblio's Option Bot, you can configure your own wheel strategy including PHGE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PHGE
- Rev/Share 0.0013
- Book/Share -0.303
- PB 1.0914
- Debt/Equity 0.3793
- CurrentRatio 0.0
- ROIC 6.2892
- MktCap 10025523.0
- FreeCF/Share -0.4923
- PFCF -0.2917
- PE -2.2235
- Debt/Assets 0.0
- DivYield 0
- ROE -0.422
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis
Published: July 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
First patient dosing in Company's Phase 2b trial marks pivotal milestone in phage therapy development program targeting antibiotic-resistant lung infections in Cystic Fibrosis patients; topline results are expected in Q1 2026 Prior Phase 1b/2a efficacy findings demonstrated complete bacterial clearance in 14.3% of patients after just 10 days of treatment Feedback from U.S. Food and Drug Administration (FDA) anticipated in H2 2025, regarding plans to evaluate investigation and use of real-world evidence linking bacterial reduction to clinical outcomes; successful alignment could potentially streamline approval pathway for this urgently needed treatment option
Read More
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)
Read More
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates.
Read More
BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Published: April 18, 2025 by: Zacks Investment Research
Sentiment: Positive
BiomX (PHGE) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NESS ZIONA, Israel, March 25, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE, the “Company” or “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided program and business updates.
Read More
BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
Published: March 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will report fourth quarter and full year 2024 financial results and provide business and program updates on Tuesday, March 25, 2025.
Read More
About BiomX Inc. (PHGE)
- IPO Date 2019-03-13
- Website https://www.biomx.com
- Industry Biotechnology
- CEO Jonathan Eitan Solomon MBA
- Employees 52